SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma

Peng-Fei Zhang; Jing Wu; Jin-Hong Luo; Ke-Sang Li; Fei Wang; Wei Huang; Yin Wu; Shui-Ping Gao; Xue-Mei Zhang; Peng-Nan Zhang

doi:doi:10.18632/aging.102313

← Back

Research Paper Volume 11, Issue 19 pp 8204—8216

SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma

Figure 3. Forced SNHG22 expression correlates with chemoresistance in EOC patients. (A) A total of 40 patients were divided into SNHG22^low and SNHG22^high groups. The diagram shows the SNHG22 expression of each group. (B) Comparison of OS curves for patients with high and low SNHG22 expression that were treated with cisplatin or paclitaxel.